Previous studies have shown that intravenously applied bacteria can accumulate in tumors and lead to sporadic tumor regression. Recently, systemic administration of attenuated Salmonella typhimurium was demonstrated to generate no significant side effects in humans, but also no antitumor responses. We report the enhanced antitumor activity in preclinical mouse cancer models of nonvirulent S. typhimurium engineered to synthesize the cytokine Interleukin-18 (IL-18). IL-18-producing bacteria (but not control bacteria) inhibit the growth of primary subcutaneous tumors as well as pulmonary metastases in immunocompetent mice challenged with syngeneic multidrug-resistant clones of murine carcinoma cell lines, without overt toxicity to normal tissues. Antitumor activity was associated with increased accumulation of T-lymphocytes and NK cells in tumors, and massive infiltration of granulocytes, as well as increased intra-tumoral production of several cytokines. In summary, these findings provide evidence of promising preclinical antitumor activity of IL-18-expressing, attenuated S. typhimurium, suggesting a novel strategy for cancer immunotherapy.
Introduction
Although reports of using bacteria to treat tumors date as far back as 1893, 1 the significant toxicity associated with this treatment precluded widespread use [1] [2] [3] and has thus far been limited to use of Bacillus Calmette-Guerin (BCG) for the treatment of superficial bladder carcinomas. 4, 5 Facultative anaerobic bacteria accumulate within tumors to concentrations of up to 10 9 colony-forming units (CFU) per gram of tumor tissue. 6, 7 The intra-tumoral accumulation of bacteria may be explained by a variety of proposed mechanisms, including access to nutrients released from necrotic cells in hypoxic areas of rapidly growing tumors, diminished bactericidal activity of macrophages and granulocytes due to lack of oxygen, suppression of the immune system in tumor regions, defective granulocyte chemotaxis due to tumor-derived cytokines such as TGF-b, and reduced antimicrobial antibodies as well as complement factors due to irregular vasculature and positive pressure within tumors. Thus, the intrinsic property of anaerobic bacteria to localize to tumors theoretically could be exploited for delivery of therapeutic molecules in a targeted manner.
Among facultative anaerobic bacteria, Salmonella typhimurium has shown promise for the development of microbial-based tumor therapies. S. typhimurium is a genetically tractable microbe, allowing genetic engineering. In preclinical animal models, intravenously (i.v.) injected Salmonella reportedly localize preferentially to solid tumors and proliferate at tumor sites. 6, 7 Recently, a lipid A negative strain of S. typhimurium was used for phase I clinical trials and was found to be safe at doses up to 10 9 CFU per m 2 body surface area. 8, 9 Elimination of lipid A prevents production of endotoxin (lipopolysaccharide), making these microorganisms nonvirulent. However, in clinical trials, lipid A-deficient Salmonella exhibited no antitumor activity.
As S. typhimurium has an excellent safety profile in humans, 7, 10 and accumulates in tumors in mouse models, we explored a strategy of engineering these nonvirulent bacteria to express genes encoding secreted proteins with potential antitumor activity. S. typhimurium are able to synthesize functional cytokines at high levels, 11 suggesting they could be exploited for in vivo production of cytokines in a tumor-targeted manner. Furthermore, their ability to grow anaerobically makes them an attractive delivery vehicle for the hypoxic regions of tumors, which tend to be resistant to radiation or chemotherapy. Moreover, from a safety perspective, bacterial delivery of cytokine genes may afford significant advantages over virus-based cancer gene therapies, including (1) the possibility to immediately terminate treatment using antibiotics and (2) avoiding insertion of foreign genetic material into the host genome, which has been associated with insertional mutagenesis leading to leukemia in the case of retrovirus-based approaches. 12 In this report, we modified attenuated Salmonella to bear a plasmid vector allowing for stable expression of interleukin-18 (IL-18). The cytokine IL-18 was originally described as an IFNg-inducing factor 13 capable of not only enhancing cytokine production by T and NK cells, but also inducing their proliferation and cytolytic activity. 14, 15 Furthermore, IL-18 leads to upregulation of MHC class I antigen expression and also favors the differentiation of CD4 þ helper T cells toward the T helper 1 (Th1) subtype. In turn, these cells promote an antitumor responses mediated by NK cells, macrophages, and CD8 þ T cells. [16] [17] [18] Thus, through its direct and indirect activities on immune cells, IL-18 has broad effects on immune cell populations implicated in fighting malignancy. Besides these effects on the immune system, IL-18 also acts as a suppressor of angiogenesis by directly inhibiting fibroblast growth factor 2-induced endothelial cell proliferation. 13, 19 Engineering tumor cells to produce IL-18 leads to reduced tumorigenicity, 20 and systemic administration of the recombinant IL-18 protein causes considerable tumor inhibition. 20, 21 Unfortunately, it has been shown that IL-18 administrated systemically causes serious side effects, 22 thus precluding its clinical application. This toxicity problem could potentially be overcome with tumor-specific targeting.
As an initial step toward this goal, we report here the use of attenuated S. typhimurium to express in vivo IL-18, showing evidence of antitumor activity in preclinical mouse cancer models and recruitment of immune and inflammatory cells into tumors, associated with enhanced intra-tumoral cytokine generation. The studies of IL-18 reported here thus extend our recent analysis of bacteria armed to express the cytokine homologous to Lymphotoxin, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpes virus entry mediator, a receptor expressed by T lymphocytes (LIGHT), a tumor necrosis factor (TNF) family member, 23 and thus demonstrate the potential of using either interleukin family cytokines or TNF family cytokines for this application.
Materials and methods
Animals, bacterial strains, cell lines, and plasmid vectors The cDNAs encoding enhanced green fluorescent protein (pEGFP, Clontech, Mountain View, California, USA) or murine IL-18 with an Igk leader sequence for directing secretion 24 were subcloned into pGEN206. 23 Protein expression of pGEN206-IL-18 was demonstrated by immunoblotting of 10 9 CFU Salmonella resuspended in Laemmli sample buffer or culture supernatants, using a monoclonal rat anti-mouse IL-18 antibody (MBL, Naka-ku, Nagoya, Japan). Additional details concerning procedures are found in our recent publication. 23 6 CFU per mouse) after 6, 13, and 20 days. After 50 days, lungs were weighed and also examined for metastases assessing the percentage of lung surface covered by metastases as follows: 0 ¼ 0, 1o20, 2 ¼ 20-50, 3X50%.
Mouse experiments
Immunohistochemistry, fluorescence activated cell sorter (FACS) analysis, and ELISA Experiments were performed essentially as described previously, 23 using fluorochrome-conjugated antibodies (BD, Franklin Lakes, New Jersey, USA), including antibodies specific for the antigens Ly-6G, DX5, CD4 and CD3, and ELISA kits for cytokines IL-1b, TNFa, IFNg, GM-CSF (eBioscience, San Diego, California, USA). Results represent amounts of cytokines per gram of protein (mean ± s.d.).
Statistics
Statistical significance was determined by 2-tailed Student's t-test for most comparisons. Two-way analysis of variance (ANOVA) was used for time-course studies. The significance of metastases scores was determined by Mann-Whitney U-test. Findings were regarded as significant, if Po0.05.
Results

IL-18 expression by attenuated Salmonella
To engineer the attenuated S. typhimurium strain purI À / msbB À for expressing IL-18, we used the plasmid pGEN206, in which a human IL-18 cDNA fused to an N-terminal leader sequence for directing secretion was expressed under control of an ompC promoter. The engineered bacteria were grown in culture, recovered by centrifugation, and the resulting cell-containing pellet and cleared culture supernatant were tested for IL-18 protein by immunoblotting, revealing the presence of IL-18 in both cells and supernatant ( Figure 1a ). The production of IL-18 under in vitro bacterial cultures is 450 pg/mg. Control Salmonella (transformed with empty plasmid) and their culture supernatants did not contain IL-18 protein.
Salmonella are non-obligate intracellular bacteria and it has been reported that they can infect many epithelial cancer cells. 25 To explore whether the attenuated Salmonella strain employed here retains infective activity, we transformed the purI À /msbB À strain of S. typhimurium with a plasmid encoding green fluorescent protein (GFP) and cocultured bacteria with various murine carcinoma cell lines, before adding antibiotic gentamycin to kill extra-cellular bacteria. Cells were then fixed, stained with DNA-binding fluorochrome, and imaged. For all six of the carcinoma lines tested, attenuated Salmonella were able to infect the cancer cells, as revealed by the presence of GFP-emitting bodies in the cytosol (see Figure 1b for representative example).
Salmonella-expressing IL-18 inhibit primary tumor growth in mice
Recently, we showed that the attenuated strain of Salmonella used here accumulates in subcutaneous tumors in vivo in mice, using luciferase expressing bacteria in conjunction with bioluminescence imaging. 23 We therefore performed studies in which control and IL-18-expressing Salmonella were compared for antitumor activity in mouse cancer models using syngeneic tumors in immunocompetent mice grown as subcutaneous tumors. For these experiments, mice were injected s.c. either with CT-26 colon (Figure 2a ) or D2F2 breast carcinoma cells (Figure 2b ). When tumors were visible, mice were treated i.v. with PBS, control Salmonella, or Salmonella containing either control (empty) vector or vector expressing mature IL-18. Marked reduction of tumor growth was observed in those mice treated with Salmonella containing the IL-18-expression vector compared with the respective control groups (Figures 2a  and b) . The suppression of tumor growth was also confirmed in experiments in which tumor-bearing mice were treated for 26 days, then killed, and the tumors were weighed (Figure 2c ). Again, IL-18-producing Salmonella demonstrated significant antitumor activity, unlike control Salmonella.
Though demonstrating potent antitumor activity, IL-18-expressing Salmonella did not cause greater systemic toxicity than the unmodified attenuated Salmonella strain. Histological analysis of multiple organs showed minimal changes that were comparable to the results obtained with control Salmonella that did not produce IL-18. For example, kidneys and lungs were completely normal, whereas spleen showed enlargement and diffuse inflammatory reactions that were similar in extent of severity in mice treated with either control of IL-18- (Supplementary Figure 1a) . Liver tissue showed slight inflammation by polymorphonuclear cells and rare granulomatosis reactions, again with the extent of toxicity similar in mice treated with either control of IL-18-producing bacteria (Supplementary Figure 1b) . Thus, addition of IL-18 did not worsen the toxicity of Salmonella, which has been shown previously to be well tolerated in humans. 8, 9 Grossly, the mice did not show decreased activity or grooming abnormalities until several weeks after Salmonella injections, when tumor burden increased, suggesting that the tumor rather than the therapy contributed to these signs of illness.
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IL-18-expressing Salmonella induce massive leukocyte infiltration into tumors, and increase recruitment of NK and T cells
We examined the histology of subcutaneous tumors in mice treated with Salmonella ( Figure 3) . By hematoxylineosin (H and E) staining, CT26 tumors derived from mice treated with PBS comprised monotonous accumulations of malignant epithelial cells with minimal stroma. Tumors from animals treated with control Salmonella or Salmonella containing only empty plasmid were similar, showing scan leukocyte infiltrates. By comparison, tumors from mice treated with IL-18-expressing Salmonella contained massive leukocyte infiltrates (Figure 3a) , particularly comprised cells with morphological characteristics of granulocytes (Supplementary Figure 2) . Immunohistochemical staining with anti-Ly-6G antibody confirmed the abundant presence of granulocytes in these tumors (Figure 3b ). These histological data suggest that IL-18-expressing Salmonella have greatly enhanced capacity to induce host inflammatory responses to tumors.
We also analyzed by FACS the numbers of DX5 þ (NK cell marker), CD3 þ /CD8 þ , and CD3 þ /CD4 þ T cells in tumors derived from CT26-bearing mice subjected to treatment with IL-18-expressing Salmonella or various controls. Compared with PBS, Salmonella, or Salmonella containing empty vector, tumors recovered from mice treated with IL-18-expressing Salmonella contained significantly more NK cells and CD4 þ T cells (Figure 4 ) but not CD8 þ T cells (not shown).
IL-18-expressing Salmonella increase intra-tumoral cytokine expression
As IL-18 is reported to induce expression of multiple cytokines, 13, 16 we analyzed the intra-tumoral levels of various cytokines that IL-18 is known to induce, including IL-1b, TNFa, IFNg, and GM-CSF. For these experiments, subcutaneous CT26 tumors were harvested from mice at 19 days after initiation of bacterial therapy. Compared with mice treated with PBS, control Salmonella, or Salmonella containing empty vector, the IL-18-expressing Salmonella induced statistically greater accumulation of all cytokines tested in tumors ( Figure 5 ). The differences were most striking for IL-1b and TNFa, whereas only marginally higher for GM-CSF. IL-18-producing Salmonella inhibit tumor growth M Loeffler et al measuring tumor burden were employed: (a) lung weight and (b) metastasis score, which measures the relative amount of the lung surface covered by tumor lesions on a 4-point scale (0-3). Compared with mice treated with PBS, control Salmonella, and Salmonella containing empty plasmid, the weight of lungs from IL-18-expressing Salmonella were markedly reduced, averaging almost half the weight of the other treatment groups and approaching the normal lung weight of B0.15 g (Figure 6a ). Metastasis scores were also substantially lower in mice treated with IL-18-expressing Salmonella (Figure 6b ). Thus, endowing Salmonella with the ability to produce IL-18 greatly enhances their antitumor activity, as evidenced by this lung metastasis model.
IL-18-expressing
Discussion
In this report, we describe preclinical assessment of a novel bacteria-based experimental therapy for cancer, in which an attenuated strain of S. typhimurium is engineered to produce the cytokine IL-18. Endowing these nonvirulent bacteria to produce mature IL-18 greatly increased their antitumor activity in immunocompetent mice, as determined in both subcutaneous primary tumor and lung metastasis models. The antitumor mechanism was associated with massive granulocyte infiltration into tumors, suggesting that IL-18 itself or other cytokines elaborated within tumors of mice treated with IL-18-expressing Salmonella are chemotactic for these leukocytes, promoting a host inflammatory response that inhibits tumor growth. Increased numbers of CD3 þ / CD4 þ T cells and DX5 þ NK cells were also found in tumors derived from mice treated with IL-18-producing Salmonella. Thus, by engineering Salmonella to express IL-18, a strong host reaction to tumors was induced, which included increased numbers of T cells and NK cells, and massive neutrophil infiltration. In contrast, inflammation of noncancerous organs was limited principally to spleen, suggesting preferential targeting of the inflammatory response to tumors. In this regard, using the same mouse cancer models, we have previously shown that the attenuated S. typhimurium strain localizes predominantly to tumors, 23 confirming several other studies that have documented tumor targeting of these facultative anaerobes, 6, 7 and extending studies that have employed Salmonella that expressed IL-18 under an eukaryotic promoter in an oral vaccination protocol. 26, 27 We found that intra-tumoral levels of several cytokines previously reported to be induced by IL-18 were increased in tumors of mice treated with IL-18-expressing Salmonella. This observation suggests that IL-18 plays an amplifying role, inducing several cytokines within tumors, and thus bringing multiple immunostimulatory and inflammatory cytokines into play, presumably contributing to the antitumor activity. Individually, some cytokines may not be essential, but in combination with others, they may make important contributors to the observed antitumor activity of IL-18-expressing Salmonella. Consequently, the mechanisms responsible for the antitumor activity of IL-18-expressing Salmonella are probably multifactoral with the predominant mechanism, possibly varying with the tumor involved, anatomical location (for example, subcutaneous vs pulmonary), mouse strain, and other variables. Further studies using mice genetically deficient in various cytokines could be employed to elucidate the relative contributions of individual cytokines to the host response to tumors in mice treated with IL-18-expressing Salmonella.
Taken together, our preclinical findings demonstrate the feasibility of a novel microbial-based approach for cancer immunotherapy involving engineering S. typhimurium to express the cytokine IL-18. The studies of IL-18 reported here extend our recent analysis of bacteria armed to express the cytokine LIGHT, a TNF family member, 23 and thus demonstrate the potential of using either interleukin family cytokines or TNF family cytokines for this application. The receptors for these two major classes of cytokines transduce signals by largely different mechanisms, 28 and the immune cell populations recruited into the antitumor response may be only partially overlapping, 23 but both types of cytokines show activity in the mouse cancer models employed here. Future studies involving other members of these families IL-18-producing Salmonella inhibit tumor growth M Loeffler et al of cytokines, as well as other types of immunomodulatory proteins, should help to reveal the full repertoire of cytokines that might be appropriate to consider for cancer immunotherapies using engineered nonvirulent S. typhimurium. Ultimately, however, human clinical trials will be needed to test the utility of such approaches and the therapeutic index of specific types of cytokines, given the important genomic differences between rodent species and humans with respect to their repertoires of genes encoding cytokines and cytokine receptors. 29 Regardless of the relative merits of various cytokines for engineering nonvirulent S. typhimurium, a bacteria- IL-18-producing Salmonella inhibit tumor growth M Loeffler et al based strategy for de novo production of cytokines may have several advantages over other approaches. For example, virus-based cytokine gene delivery is difficult to terminate, given the general lack of antiviral drugs that could stop viral infection if toxicity was encountered. Most of the currently used viruses also lack biological features that might preferentially target them to tumors. Furthermore, recombinant cytokines are typically expensive to produce and they also lack tumor-targeting features, often causing severe systemic inflammatory reactions that limit clinical use. In contrast, genetically engineered bacteria are inexpensively produced, can selectively target tumors, and are readily eradicated by antibiotic therapy in the event of toxicity. These advantages therefore warrant further preclinical evaluations of cytokine-producing bacteria as a novel microbial approach to cancer immunotherapy.
